Last reviewed · How we verify

ADMA Biologics, Inc. — Portfolio Competitive Intelligence Brief

ADMA Biologics, Inc. pipeline: 2 marketed, 0 filed, 1 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 1 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Bivigam Bivigam marketed Other
Asceniv™ Asceniv™ marketed Intravenous immunoglobulin (IVIG) Polyclonal immunoglobulins (IgG) Immunology
RI-002 RI-002 phase 3 Intravenous immunoglobulin (IVIG) Immunology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Baxalta now part of Shire · 1 shared drug class
  2. Bio Products Laboratory · 1 shared drug class
  3. Biotest · 1 shared drug class
  4. CSL Behring · 1 shared drug class
  5. CSL Limited · 1 shared drug class
  6. Grifols Biologicals, LLC · 1 shared drug class
  7. Grifols Therapeutics LLC · 1 shared drug class
  8. Instituto Grifols, S.A. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for ADMA Biologics, Inc.:

Cite this brief

Drug Landscape (2026). ADMA Biologics, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/adma-biologics-inc. Accessed 2026-05-16.

Related